一名复发性弥漫性大B细胞淋巴瘤患者在接受大剂量化疗和自体干细胞移植后接受利妥昔单抗单药治疗，实现持久完全缓解。
Durable complete remission in a patient with recurrent DLBCL receiving rituximab monotherapy after high-dose chemotherapy and autologous stem cell transplantation.
作者信息
Pircher Andreas, Gassner Eva Maria, Steurer Michael, Wolf Dominik
机构信息
Department of Hematology and Oncology, Internal Medicine V, Medical University Innsbruck, Innsbruck, Austria.
出版信息
BMJ Case Rep. 2012 Jul 3;2012:bcr0220125856. doi: 10.1136/bcr.02.2012.5856.
Abstract
The optimal management of patients with diffuse large B cell lymphoma relapsing after autologous haematopoetic stem cell transplantation (HCT) is difficult and no standard treatment has been defined. The authors here report the case of a rituximab-naive patient who relapsed after HCT and was cured with rituximab monotherapy.
摘要
弥漫性大B细胞淋巴瘤患者自体造血干细胞移植（HCT）后复发的最佳管理很困难，且尚未确定标准治疗方法。本文作者报告了1例未使用过利妥昔单抗的患者，该患者HCT后复发，接受利妥昔单抗单药治疗后治愈。
Zotero 插件